

**MECHANISTIC EVALUATION OF MENSTRUAL
BLOOD-DERIVED ENDOMETRIAL STEM CELLS
IN MUTINE MODELS OF ALSOHOLIC AND
NON-ALCOHOLIC FATTY LIVER DISEASE**

JIANG YAN

UNIVERSITI SAINS MALAYSIA

2025

**MECHANISTIC EVALUATION OF MENSTRUAL
BLOOD-DERIVED ENDOMETRIAL STEM CELLS
IN MUTINE MODELS OF ALCOHOLIC AND
NON-ALCOHOLIC FATTY LIVER DISEASE**

by

JIANG YAN

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

March 2025

ACKNOWLEDGEMENT

I sincerely grateful to my principal supervisors, Dr. Emmanuel Jairaj Moses and Prof. Lin Juntang, for their exceptional insights, extensive knowledge, and unwavering encouragement during the course of my PhD. Their guidance has been crucial to the completion of this thesis.

I would also like to extend my heartfelt thanks to my co-supervisors, Assoc. Prof. Dr. Du Jiang and Prof. Dr. Narazah Mohd Yusoff, for their significant contributions to revising my thesis, papers, and providing essential guidance during my experiments. Their assistance was crucial in overcoming numerous challenges during my lab work, and their encouragement played a vital role in the achievements listed in my awards section.

I am sincerely thankful to my wonderful lab mates and friends at Universiti Sains Malaysia and Xinxiang Medical University, including Ji Xiang, Liu Xinlei, Yaashini Rajasegaran, Muhammad Adam Bin Azlan, Xu Bo, Du Qizhang, Li Yujie, He Yanan, and Sun Yuliang, among others. Their constant support in both my academic and personal life gave me the strength and courage to persevere. My gratitude also extends to the staff and lecturers who worked alongside me in the same research cluster.

I owe my deepest gratitude to my beloved parents and husband. Their unconditional love and support provided me with the strength to overcome all challenges. They have been my driving force throughout this PhD journey.

Lastly, I wish to convey my gratitude to Universiti Sains Malaysia and Xinxiang Medical University for the fellowships that supported my tuition and living expenses during my PhD studies.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	xiv
LIST OF FIGURES	xvi
LIST OF SYMBOLS	xxviii
LIST OF ABBREVIATIONS	xxix
LIST OF APPENDICES	xxxv
ABSTRAK	xxxvi
ABSTRACT	xxxviii
CHAPTER 1 INTRODUCTION	1
1.1 Research Background.....	1
1.1.1 Alcohol-associated liver diseases (ALD).....	1
1.1.2 Non-alcoholic fatty liver diseases (NAFLD)	2
1.2 Rationale and importance of the study	6
1.2.1 Rational and importance of MenSCs in ALD	6
1.2.2 Rational and importance of MenSCs in NAFLD.....	8
1.3 Hypothesis and objective of the study.....	10
1.3.1 Hypothesis	10
1.3.2 Objective of the study	10
CHAPTER 2 LITERATURE REVIEW	12
2.1 Overview of alcohol-associated liver disease (ALD)	12
2.1.1 The prevalence of ALD.....	12
2.1.2 ALD pathogenesis	13
2.1.2(a) Dysregulation of alcohol metabolic pathways.....	14

	2.1.2(b)	Dysregulation of metabolic pathways in the liver by excessive consumption of alcohol	16
2.1.3		Current management and treatment strategies for ALD	23
	2.1.3(a)	Alcohol abstinence: a core management strategy	23
	2.1.3(b)	Nutritional support in ALD care	24
	2.1.3(c)	Pharmacological treatment for ALD	25
	2.1.3(d)	Liver transplantation: the definitive treatment approach	26
	2.1.3(e)	Advances in targeted therapies for ALD	26
2.2		Overview of NAFLD	28
	2.2.1	The prevalence of NAFLD	28
	2.2.2	Natural history of NAFLD	29
	2.2.3	Pathogenesis of NAFLD development	30
	2.2.3(a)	Two-hit hypothesis	30
	2.2.3(b)	Multiple hits hypothesis	30
	2.2.4	Underlying mechanisms of NAFLD pathogenesis	31
	2.2.4(a)	Lipid Accumulation in NAFLD progression	31
	2.2.4(b)	Inflammatory response	32
	2.2.4(c)	Oxidative stress	32
	2.2.4(d)	Endoplasmic reticulum (ER) stress	33
	2.2.4(e)	Autophagy	34
	2.2.4(f)	Fibrosis and cirrhosis	34
	2.2.5	Current management and treatment approaches for NAFLD	35
	2.2.5(a)	Dietary interventions for NAFLD management	35
	2.2.5(b)	Weight management and lifestyle modifications	36
	2.2.5(c)	Antioxidant therapy: the role of Vitamin E	36
	2.2.5(d)	Pioglitazone therapy for insulin sensitization	36
	2.2.5(e)	Emerging therapeutic and surgical interventions	37

2.3	A brief introduction to Mesenchymal stem cells (MSCs).....	41
2.3.1	Types of MSCs and MSC derived components	41
2.3.2	Characteristics of MSCs.....	43
2.3.3	Roles of MSCs and MSC derived components.....	43
2.3.3(a)	Immunomodulatory actions	43
2.3.3(b)	Anti-inflammatory effects	44
2.3.3(c)	Tissue repair and regeneration ability.....	44
2.3.3(d)	Facilitation of hematopoiesis.....	46
2.3.3(e)	Anti-apoptotic properties	47
2.3.3(f)	Roles of MSCs in mitochondrial transfer	47
2.3.4	Summary and perspectives.....	48
2.3.5	MSCs as a potential therapeutic strategy for ALD	49
2.3.5(a)	MSCs enhanced liver function and lipid metabolism in ALD	49
2.3.5(b)	MSCs mitigated inflammation in ALD	49
2.3.5(c)	MSCs improved the regulation of oxidative stress.....	50
2.3.5(d)	Combinatorial treatment approach with MSCs enhanced therapeutic efficacy.....	50
2.3.5(e)	Clinical trials involving the use of MSCs to treat ALD	54
2.3.6	Therapeutic potential of MSCs in treating NAFLD.....	54
2.3.6(a)	MSCs enhanced glucose and lipid metabolism in NAFLD/NASH.....	55
2.3.6(b)	MSCs reduced inflammatory effects in NAFLD/NASH.....	56
2.3.6(c)	MSCs regulating oxidative and ER stress in NAFLD/NASH.....	57
2.3.6(d)	MSCs alleviated liver fibrosis in NAFLD/NASH.....	58
2.3.6(e)	Summary of preclinical studies utilizing MSCs as a therapeutic strategy to treat NAFLD	59

CHAPTER 3	METHODOLOGY	75
3.1	Overview of the study	75
3.2	Isolation and propagation of human menstrual blood-derived endometrial stem cells (MenSCs)	84
3.2.1	Isolation of MenSCs	84
3.2.2	Propagation of MenSCs	84
3.3	Immunophenotyping of MenSCs	85
3.4	MenSCs labelling and imaging	86
3.5	Establishment and treatment of ALD mouse models	88
3.5.1	Establishment of ALD mouse model	88
3.5.2	Treatment of ALD mouse model	89
3.5.3	Method of delivery	89
3.5.4	Orbital blood collection in mouse	90
3.5.5	Harvesting and processing of mouse liver tissues	90
3.6	Establishment and treatment of NAFLD mouse model	92
3.6.1	Establishment of NAFLD mouse model	92
3.6.2	Treatment of NAFLD mouse model	92
3.6.3	Method of delivery	93
3.6.4	Orbital blood collection in mouse	93
3.6.5	Harvesting and processing of mouse liver tissues	93
3.7	Biochemical analysis of liver function	94
3.7.1	Evaluation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for ALD and NAFLD	94
3.7.2	Assessment of triglycerides (TG) and total cholesterol (TC) for ALD	95
3.7.3	Quantification of Glutathione (GSH) and Malondialdehyde (MDA) for ALD	96
3.7.4	Measurement of Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH) for ALD	97

3.7.5	Glucose Tolerance Test (GTT) and Insulin Resistance Test (ITT) for NAFLD	98
3.8	Gene expression analysis	99
3.8.1	Total RNA extraction	99
3.8.2	RNA concentration determination	100
3.8.3	The process of converting RNA into cDNA	100
3.8.4	qPCR experiment	101
3.9	RNA-sequencing and biological analysis	106
3.9.1	Transcriptome sequencing.....	106
3.9.2	Bioinformatics analysis	106
3.10	Protein extraction and quantification analysis	107
3.10.1	Protein extraction	107
3.10.2	Protein quantification via BCA assay	107
3.11	Protein expression analysis via western blot.....	109
3.11.1	Preparation of buffers.....	109
3.11.2	SDS-PAGE gel electrophoresis.....	109
3.11.3	Protein electrophoresis	111
3.11.4	Transfer of protein from gel to membrane	112
3.11.5	Blocking of membrane	112
3.11.6	Incubation with primary antibody	112
3.11.7	Incubation with secondary antibody	114
3.11.8	Imaging and protein band analysis.....	115
3.12	Histological assessment.....	116
3.12.1	Hematoxylin & Eosin (H&E) staining	116
3.12.2	Oil-Red O staining	117
3.12.3	Masson trichrome staining	117
3.12.4	Periodic Acid Schiff (PAS) staining	118
3.12.5	TdT-mediated dUTP nick end labeling (TUNEL) staining	119

3.12.6	Immunohistochemical (IHC) staining	119
3.13	Statistical analysis	121
CHAPTER 4 RESULTS.....		122
4.1	Characterization and biodistribution of MenSCs	122
4.1.1	Characterization of MenSCs	122
4.1.2	Biodistribution of DiI-labeled MenSCs	123
4.2	MenSCs improved liver metabolic imbalances in ALD mice.....	126
4.2.1	MenSCs reduced ALT and AST levels in ALD mice.....	126
4.2.2	MenSCs reduced TG and TC levels in ALD mice.....	126
4.2.3	MenSCs reduced ADH and ALDH levels in ALD mice	127
4.2.4	MenSCs increased GSH level and reduced MDA level in ALD mice	128
4.3	MenSCs inhibited lipid synthesis and improved lipid oxidation in ALD mice	130
4.3.1	Histopathological assessment.....	130
4.3.2	RNA sequence analysis	132
4.3.2(a)	Heatmap analysis	132
4.3.2(b)	Gene ontology (GO) analysis	133
4.3.2(c)	Gene set enrichment analysis (GSEA)	134
4.3.3	MenSCs regulated key genes in lipid metabolic pathways	135
4.3.4	MenSCs reduced key proteins involved in lipid synthesis.....	137
4.4	MenSCs regulated inflammatory and apoptotic in ALD mice.....	140
4.4.1	Histopathological assessment.....	140
4.4.2	RNA sequence analysis	142
4.4.2(a)	Heatmap analysis	142
4.4.2(b)	GO analysis.....	143
4.4.2(c)	GSEA	144

4.4.3	MenSCs regulated the expression of inflammatory cytokine genes.....	145
4.4.4	MenSCs regulated the expression of inflammation cytokine proteins.....	146
4.5	MenSCs regulated autophagy, ER stress and oxidative stress in ALD mice	148
4.5.1	RNA sequence analysis.....	148
4.5.1(a)	Heatmap analysis.....	148
4.5.1(b)	GO analysis.....	149
4.5.1(c)	GSEA.....	150
4.5.2	MenSCs enhanced autophagy in ALD mice.....	151
4.5.2(a)	MenSCs regulated the expression of autophagy genes.....	151
4.5.2(b)	MenSCs regulated the expression of autophagy proteins.....	152
4.5.3	MenSCs reduced ER stress in ALD mice.....	154
4.5.3(a)	MenSCs decreased the expression of ER stress genes.....	154
4.5.3(b)	MenSCs decreased the expression of ER stress proteins.....	155
4.5.4	MenSCs reduced oxidative stress in ALD mice.....	157
4.5.4(a)	MenSCs decreased the expression of oxidative stress genes.....	157
4.5.4(b)	MenSCs decreased the expression of oxidative stress proteins.....	158
4.6	MenSCs reduced fibrosis in ALD mice.....	161
4.6.1	Histopathological assessment.....	161
4.6.2	RNA sequence analysis.....	161
4.6.2(a)	Heatmap analysis.....	161
4.6.2(b)	GO analysis.....	162
4.6.2(c)	GSEA.....	163
4.6.3	MenSCs decreased the expression of fibrosis genes.....	164

4.7	MenSCs improved liver metabolic imbalance in NAFLD mice	166
4.7.1	MenSCs reduced ALT and AST levels in NAFLD mice.....	166
4.7.2	MenSCs improved insulin sensitivity and glucose metabolism in NAFLD mice.....	166
4.7.3	MenSCs enhanced glycogen accumulation ability in NAFLD mice	167
4.8	MenSCs inhibited lipid synthesis and improved lipid oxidation in NAFLD mice	169
4.8.1	Histopathological assessment.....	169
4.8.2	RNA sequence analysis	171
4.8.2(a)	Heatmap analysis	171
4.8.2(b)	GO analysis.....	172
4.8.2(c)	GSEA.....	173
4.8.3	MenSCs regulated key genes in lipid metabolic pathways	174
4.8.4	MenSCs reduced key proteins involved in lipid synthesis.....	176
4.9	MenSCs regulated inflammatory and apoptotic in NAFLD mice.....	179
4.9.1	Histopathological assessment.....	179
4.9.2	RNA sequence analysis	180
4.9.2(a)	Heatmap analysis	180
4.9.2(b)	GO analysis.....	181
4.9.2(c)	GSEA.....	182
4.9.3	MenSCs regulated the expression of inflammatory cytokine genes.....	183
4.9.4	MenSCs regulated the expression of inflammatory cytokine proteins	184
4.10	MenSC regulated autophagy, ER stress and oxidative stress in NAFLD mice	188
4.10.1	RNA sequence analysis	188
4.10.1(a)	Heatmap analysis	188
4.10.1(b)	GO analysis.....	189

4.10.1(c)	GSEA.....	190
4.10.2	MenSCs enhanced autophagy in NAFLD mice	191
4.10.2(a)	MenSCs regulated the expression of autophagy genes	191
4.10.2(b)	MenSCs regulated the expression of autophagy proteins	192
4.10.3	MenSCs reduced ER stress in NAFLD mice	193
4.10.3(a)	MenSCs decreased the expression of ER stress genes	193
4.10.3(b)	MenSCs decreased the expression of ER stress proteins	194
4.10.4	MenSCs reduced oxidative stress in NAFLD mice	195
4.10.4(a)	MenSCs decreased the expression of oxidative stress genes	195
4.10.4(b)	MenSCs decreased the expression of oxidative stress proteins.....	196
4.11	MenSC reduced fibrosis in NAFLD mice.....	198
4.11.1	Histopathological assessment.....	198
4.11.2	RNA-sequence analysis.....	198
4.11.2(a)	Heatmap analysis	198
4.11.2(b)	GO analysis.....	199
4.11.2(c)	GSEA.....	200
4.11.3	MenSCs decreased the expression of fibrosis genes	201
CHAPTER 5 DISCUSSION		203
5.1	MenSCs portrayed similar characteristics to mesenchymal stromal cells ...	203
5.2	ALD and NAFLD <i>in vivo</i> mice models were successfully established in this study	206
5.3	MenSCs treatment restored biochemical imbalances in ALD and NAFLD mice	210
5.4	MenSCs treatment modulated lipid metabolism in ALD and NAFLD mice	213

5.4.1	The impact of MSCs on lipid synthesis in ALD and NAFLD mice	213
5.4.2	The impact of MenSCs on lipid oxidation in ALD and NAFLD mouse models	214
5.4.3	MenSCs treatment targeted similar pathways of lipid metabolism in ALD and NAFLD mice	215
5.4.4	MenSCs treatment affected different genes and proteins of the lipid metabolic pathways in ALD and NAFLD mice	216
5.5	MenSCs treatment alleviated inflammation and apoptosis in ALD and NAFLD mice	219
5.5.1	The impact of MenSCs on inflammation in ALD and NAFLD mice	219
5.5.2	The impact of MenSCs on apoptosis in ALD and NAFLD mice	220
5.5.3	MenSCs treatment affected similar immunomodulatory and apoptotic pathways in ALD and NAFLD	222
5.5.4	MenSCs treatment affected different genes and protein in inflammatory and apoptotic pathways in ALD and NAFLD	223
5.6	MenSCs treatment reduced hepatic stress and induced autophagy in AFLD and NAFLD mice	226
5.6.1	The impact of MenSCs on autophagy in ALD and NAFLD mice	226
5.6.2	The impact of MenSCs on ER stress and oxidative stress in ALD and NAFLD mice	227
5.6.3	MenSCs treatment affected similar molecular pathways on hepatic stress in ALD and NAFLD	229
5.6.4	MenSCs treatment affected different gene and proteins related to hepatic stress in ALD and NAFLD	230
5.7	MenSCs treatment alleviated fibrosis in ALD and NAFLD mice	234
5.7.1	MenSCs treatment reversed fibrotic conditions in ALD and NAFLD mice	234
5.7.2	MenSCs treatment affected similar molecular pathways of fibrosis in ALD and NAFLD mice	235
5.7.3	MenSCs treatment affected different genes and proteins involved in fibrotic molecular pathways in ALD and NAFLD ...	235

5.8	Summary of molecular mechanisms induced by treatment of MenSC in ALD and NAFLD mice	238
5.8.1	MenSCs improved biochemical in ALD and NAFLD.....	238
5.8.2	MenSCs reduced fat accumulation in ALD and NAFLD	240
5.8.3	MenSCs reduced inflammation and apoptosis in ALD and NAFLD.....	243
5.8.4	MenSCs improved autophagy and reduced ER stress and oxidative stress in ALD and NAFLD.....	246
5.8.5	MenSCs reduced fibrosis in ALD and NAFLD.....	249
CHAPTER 6 CONCLUSION AND FUTURE RECOMMENDATIONS....		251
6.1	Conclusion.....	251
6.2	Future recommendations	253
REFERENCES.....		256
APPENDICES		
LIST OF PUBLICATIONS		

LIST OF TABLES

	Page
Table 1.1	Comparison of the pathogenesis of ALD and NAFLD.....4
Table 2.1	Comparison of ALD and NAFLD.....38
Table 2.2	Summary of <i>in vivo</i> preclinical studies that utilize MSCs as a treatment for ALD.....51
Table 2.3	Summary of <i>in vitro</i> studies to evaluate MSCs as a potential therapeutic strategy for NAFLD/NASH60
Table 2.4	Summary of <i>in vivo</i> studies to evaluate MSCs as a potential therapeutic strategy for NAFLD/NASH64
Table 3.1	ALT/AST standard curve procedure95
Table 3.2	Reverse transcription system matching method..... 101
Table 3.3	qPCR reaction system matching method 102
Table 3.4	List of primers 103
Table 3.5	Composition of separating gel (~5ml) for SDS-PAGE..... 110
Table 3.6	Composition of stacking gel per gel (~2ml) for SDS-PAGE..... 110
Table 3.7	Protein lengths and corresponding gel concentrations..... 111
Table 3.8	List of antibodies..... 113
Table 5.1	Biochemical analysis following MenSCs treatment in ALD and NAFLD239
Table 5.2	Lipid metabolism analysis following MenSCs treatment in ALD and NAFLD.....241
Table 5.3	Inflammation and apoptosis analysis following MenSCs treatment in ALD and NAFLD244
Table 5.4	Autophagy, ER stress, and oxidative stress analyses following MenSCs treatment in ALD and NAFLD247

Table 5.5	Fibrosis analysis following MenSCs treatment in ALD and NAFLD	250
-----------	--	-----

LIST OF FIGURES

	Page
Figure 2.1	Spectrum of ALD, risk factors, and comorbidities (Mackowiak et al., 2024). 14
Figure 2.2	Metabolic pathways affected in the liver by excessive consumption (Xiao, 2020). 16
Figure 2.3	The natural history of NAFLD (Guo <i>et al.</i> , 2022).29
Figure 2.4	MSCs derived from different tissues develop into multiple cell types in vitro (Zhang et al., 2020b).42
Figure 2.5	The therapeutic actions of MSCs and MSC-derived secretory factors in NAFLD (Jiang <i>et al.</i> , 2024).55
Figure 3.1	Establish the ALD mouse model..... 78
Figure 3.2	Establish the NAFLD mouse model. 79
Figure 3.3	Elucidating the role of MenSCs in amelioration of ALD.80
Figure 3.4	Elucidating the role of MenSCs in amelioration of NAFLD.82
Figure 3.5	Establishment of ALD mouse model. Schematic illustration depicting the timeline and approach used to evaluate the effects of MenSCs transplantation in ALD mice induced with the Lieber-DeCarli diet.89
Figure 3.6	Establishment of NAFLD mouse model. Schematic illustration depicting the timeline and approach used to evaluate the effects of MenSCs transplantation in NAFLD mice induced with the HFD.92
Figure 4.1	Morphology and immunophenotypes of MenSCs. (A) Morphologic images of clones formed by MenSCs (P0 and P3) captured under a microscope at 100× magnification. Scale bars: 100 μm. (B) Flow cytometry analysis revealed that P3 MenSCs exhibited MSCs-specific CD markers. Red curve represents isotype controls and blue area indicates CD markers expression. ... 123

Figure 4.2	The biodistribution of MenSCs in liver tissues following tail vein injection in the AFLD mouse model. (A) MenSCs were labeled with DiI before injection. (B) One week later, MenSCs were analyzed in the liver tissue of both the Control group and the AH group. Scale bars: 100 μ m.....	124
Figure 4.3	The biodistribution of MenSCs following tail vein injection in the NAFLD mouse model. One-week post-injection, the presence of MenSCs in the liver was examined in the PBS/DiI and MenSCs/DiI groups. Scale bars, 100 μ m.	125
Figure 4.4	Effect of MenSCs transplantation on ALT and AST levels in ALD mice. Serum AST and ALT levels were measured in the specified groups (n=10). In the statistical plots, circles represented individual mice, with data presented as the mean \pm SEM. ** P < 0.01, *** P < 0.001.	126
Figure 4.5	Effect of MenSCs transplantation on TG and TC levels in ALD mice. (A) Serum and liver tissue TG levels in the specified groups (n=10). (B) Serum and liver tissue TC levels in the specified groups (n=5). In all statistical plots, circles represented individual mice, with data presented as the mean \pm SEM. ** P < 0.01, *** P < 0.001.....	127
Figure 4.6	Effectiveness of MenSCs treatment on enzymatic activity of ADH and ALDH in ALD. (A) Serum ADH levels in the specified groups (n=5). (B) Serum ALDH levels in the specified groups (n=5). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.	128
Figure 4.7	The impact of MenSCs administration on MDA and GSH levels in ALD. (A) Serum MDA levels in the indicated groups (n=5). (B) Serum GSH levels in the specified groups (n=5). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. ** P < 0.01, *** P < 0.001.	129

Figure 4.8	Histopathological assessment of AFLD mouse livers. Representative images of H&E staining and Oil red O staining of liver sections from the specified groups(n=3), the liver tissue in the AH group showed significant damage and fat vacuoles (black arrows) and lipid droplets (green arrows). Scale bars: 100 μ m.	131
Figure 4.9	Representative heatmap showed key genes in lipid metabolism regulation derived from mRNA-seq. data. Red indicated relatively higher expression levels, while blue signified relatively lower expression levels. Each column corresponds to an individual sample, and each row corresponds to a specific gene (n=3).	133
Figure 4.10	GO enrichment analysis of lipid metabolism-related pathways. (A) Comparison between the AH group and the Control group. (B) Comparison between the AH/MenSCs group and the AH group. ...	134
Figure 4.11	GSEA identified pathways associated with lipid metabolism across different groups. The analysis includes comparisons between the Control group and the AH group, as well as between the AH/MenSCs group and the AH group.	135
Figure 4.12	Effect of MenSCs treatment on lipid synthesis and lipid oxidation genes expression in ALD mice. (A) Relative mRNA levels of <i>Fasn</i> , <i>Srebp1</i> , and <i>Scd1</i> were examined using qPCR. (B) Relative mRNA levels of <i>CPT1</i> , <i>Acadm</i> , and <i>PPARα</i> were examined using qPCR. In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. *** $P < 0.001$	137
Figure 4.13	Effect of MenSCs treatment on lipid synthesis proteins expression in ALD mice. Protein levels of ACC-1, Srebp1, and Fasn were detected by Western blotting. In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * $P < 0.05$, ** $P < 0.01$	139
Figure 4.14	Histopathological assessment of mouse livers. The immunofluorescence images displayed CD68 ⁺ macrophages and TUNEL ⁺ apoptotic cells in liver samples from the specified groups (n=6). Scale bars: 100 μ m. Quantification of the total number of	

	CD68 ⁺ and TUNEL ⁺ cells was provided. In all statistical plots, circles represented individual mice, and data were shown as the mean \pm SEM. *** P <0.001.	141
Figure 4.15	Representative heatmap showed key genes in inflammation and apoptosis regulation derived from mRNA-seq data. Red indicated relatively higher expression levels, while blue signifies relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene(n=3).	142
Figure 4.16	GO enrichment analysis of inflammation and apoptosis related pathways. (A) Comparison between the AH group and the Control group. (B) Comparison between the AH/MenSCs group and the AH group.....	143
Figure 4.17	GSEA identified potential pathways related to inflammation and apoptosis across different groups. The analysis includes comparisons between the Control group and the AH group, as well as between the AH/MenSCs group and the AH group.	144
Figure 4.18	Effect of MenSCs treatment on inflammatory genes expression in ALD mice. qPCR analysis revealed significant changes in the expression of pro-inflammatory cytokines (<i>IL-1β</i> , <i>IL-6</i> , <i>TNF-α</i> , and <i>CCL2</i>) and anti-inflammatory cytokine <i>IL-10</i> in the specified groups (n=5). In all statistical plots, circles represent individual mice, and data were presented as the mean \pm SEM. * P <0.05, ** P <0.01, *** P <0.001.	146
Figure 4.19	Effect of MenSCs treatment on the phosphorylation status of p65 and IKK β subunit proteins expression in ALD mice. Western blot analysis revealed altered expression levels of p-IKK β , IKK β , p65 and p-p65 in the specified groups(n=2). In all statistical plots, circles represent individual mice, and the data were presented as the mean \pm SEM. * P <0.05, ** P <0.01.	147
Figure 4.20	Representative heatmap showed key genes autophagy, ER stress, and oxidative stress regulation derived from mRNA-seq data. Red indicated relatively higher expression levels, while blue signifies	

	relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene (n=3).	149
Figure 4.21	GO enrichment analysis of autophagy, ER stress, and oxidative stress related pathways. (A) Comparison between the AH group and the Control group. (B) Comparison between the AH/MenSCs group and the AH group.....	150
Figure 4.22	GSEA analysis for pathways related to autophagy, ER stress, and oxidative stress across different groups. The analysis includes comparisons between the Control group and the AH group, as well as between the AH/MenSCs group and the AH group.	151
Figure 4.23	Effect of MenSCs treatment on autophagy-related genes expression in ALD mice. qPCR analysis revealed significant changes in the expression of autophagy genes <i>Beclin1</i> , <i>LC3</i> , and <i>p62</i> in the indicated groups (n=5). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. ** P <0.01, *** P <0.001.	152
Figure 4.24	Effect of MenSCs treatment on autophagy proteins expression in ALD mice. The protein levels of LC3 and p62 were analyzed by Western blotting. For all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * P < 0.05, ** P < 0.01.....	154
Figure 4.25	Effect of MenSCs treatment on ER stress-related genes expression in ALD mice. qPCR analysis showed significant changes in the expression of ER stress genes <i>ATF4</i> , <i>ATF6</i> , and <i>CHOP</i> across the specified groups(n=5). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * P <0.05, *** P <0.001.	155
Figure 4.26	Effect of MenSCs treatment on ER stress proteins expression in ALD mice. Western blotting was used to assess the protein expression of ATF4 and p-eIF2 α . In all statistical plots, circles represent individual mice, and data were presented as the mean \pm SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.	157

Figure 4.27	Effect of MenSCs treatment on oxidative stress genes expression in ALD mice. qPCR analysis demonstrated notable changes in the expression of oxidative stress genes <i>NRF2</i> , <i>HO-1</i> , and <i>GCLC</i> in the indicated groups (n=5). In all statistical plots, circles represent individual mice, and data were presented as the mean \pm SEM. *** $P < 0.001$	158
Figure 4.28	Effect of MenSCs treatment on oxidative stress proteins expression in ALD mice. Western blotting was used to assess the protein expression levels of KEAP1, Cytochrome C, and HO-1. In all statistical plots, circles represent individual mice, and data were presented as the mean \pm SEM. * $P < 0.05$, ** $P < 0.01$	160
Figure 4.29	Histopathological assessment of AFLD mouse livers. The extent of liver fibrosis was evaluated by Masson trichrome staining using liver tissues from the Control group, the AH group, and the AH/MenSCs group. Scale bars: 150 μ m.	161
Figure 4.30	Representative heatmap showed key genes in fibrosis regulation derived from mRNA-seq data. Red indicated relatively higher expression levels, while blue signifies relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene (n=3).	162
Figure 4.31	GO enrichment analysis of fibrosis related pathways. (A) Comparison between the AH group and the Control group. (B) Comparison between the AH/MenSCs group and the AH group. ...	163
Figure 4.32	GSEA identified potential pathways related to fibrosis across different groups. The analysis includes comparisons between the Control group and the AH group, as well as between the AH/MenSCs group and the AH group.	163
Figure 4.33	Effect of MenSCs treatment on fibrosis related genes expression in ALD mice. qPCR analysis revealed significant changes in the expression of <i>Coll1a1</i> , <i>Ctgf</i> , α -SMA, and <i>TGF-β</i> genes across the specified groups (n=5). In all statistical plots, circles represent	

	individual mice, and data were presented as the mean \pm SEM. * P <0.05, ** P <0.01, *** P <0.001.....	165
Figure 4.34	Effect of ALT and AST by MenSCs transplantation in NAFLD. Serum AST and ALT levels in the specified groups (n=10). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. *** P < 0.001.	166
Figure 4.35	Evaluation of glucose metabolism and insulin sensitivity in NAFLD mice treated with MenSCs. (A) GTT was conducted in PBS or MenSCs transplanted mice after 20 weeks of HFD administration (n=8). (B) ITT was conducted in PBS or MenSC-treated mice after 20 weeks of HFD administration (n=8). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.	167
Figure 4.36	Histological assessment and glycogen content in liver tissues of NAFLD mice treated with MenSCs. PAS-stained liver sections and quantification of glycogen content in samples from mice injected with PBS or MenSCs that and fed either a HFD or NCD for 20 weeks (n=9). Scale bars: 150 μ m.	168
Figure 4.37	Histopathological assessment of mouse livers. Representative images of liver sections stained with H&E staining and Oil red O from the specified groups(n=7), the liver tissue in the AH group showed significant damage and fat vacuoles (black arrows) and lipid droplets (green arrows). Scale bars: 150 μ m.	170
Figure 4.38	Representative heatmap showed key genes in lipid metabolism regulation derived from mRNA-seq data. Red indicated relatively higher expression levels, while blue signifies relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene (n=3).	172
Figure 4.39	GO enrichment analysis lipid metabolism-related pathways. (A) Comparison between the HFD group and the NCD group. (B)	

	Comparison between the HFD/MenSCs group and the HFD group.	173
Figure 4.40	GSEA identified potential pathways related to lipid metabolism across different groups. The analysis includes comparisons between the HFD group and the NCD group, as well as between the HFD/MenSCs group and the HFD group.....	174
Figure 4.41	Effect of MenSCs treatment on lipid synthesis and oxidation genes expression in NAFLD mice. (A) Relative mRNA levels of <i>Fasn</i> , <i>Srebp1</i> , and <i>SCD1</i> were examined using qPCR. (B) Relative mRNA levels of <i>PPARα</i> , <i>Acadm</i> , and <i>CPT1</i> were examined using qPCR. In all statistical plots, circles represent individual mice, with data presented as the mean ± SEM. * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001.....	176
Figure 4.42	Effect of MenSCs treatment on lipid synthesis protein expression in NAFLD mice. Western blotting was used to assess the protein expression of ACC-1, Srebp1, and Fasn. In all statistical plots, circles represent individual mice, with data presented as the mean ± SEM. * <i>P</i> < 0.05, ** <i>P</i> < 0.01.....	178
Figure 4.43	Histopathological assessment of NAFLD mouse livers. Immunofluorescence images displayed CD68 ⁺ macrophages in liver samples from the specified groups. Scale bars: 100 μm. Quantification of the total CD68 ⁺ macrophages was provided. In all statistical plots, circles represented individual mice, with data presented as the mean ± SEM. *** <i>P</i> < 0.001.	179
Figure 4.44	Histopathological assessment of NAFLD mouse livers. Immunofluorescence images showed the presence of TUNEL ⁺ apoptotic cells in liver samples from the specified groups (n=6). Scale bars: 100 μm. Quantification of the total number of TUNEL ⁺ cells was provided. In all statistical plots, circles represent individual mice, with data presented as the mean ± SEM. *** <i>P</i> < 0.001.	180

Figure 4.45	Representative heatmap showed key genes in inflammation and apoptosis regulation derived from mRNA-seq. data. Red indicated relatively higher expression levels, while blue signifies relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene(n=3).	181
Figure 4.46	GO enrichment analysis inflammation and apoptosis related pathways. (A) Comparison between the HFD group and the NCD group. (B) Comparison between the HFD/MenSCs group and the HFD group.	182
Figure 4.47	GSEA identified potential pathways related to inflammation and apoptosis across different groups. The analysis includes comparisons between the HFD group and the NCD group, as well as between the HFD/MenSCs group and the HFD group.	183
Figure 4.48	Effect of MenSCs treatment on pro-inflammatory cytokine genes expression in NAFLD mice. qPCR analysis revealed significant changes in the expression of pro-inflammatory cytokines (<i>TNF-α</i> , <i>IL-1β</i> , and <i>CCL2</i>) and anti-inflammatory (<i>IL-10</i>) cytokine in the specified groups (n=4). in all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. ** <i>P</i> <0.01, *** <i>P</i> <0.001.	184
Figure 4.49	Effect of MenSCs treatment on inflammatory pathways in NAFLD mice. Western blot analysis revealed altered expression levels of p-IKK β , IKK β , p-p65, and p65 in the specified groups (n=2). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> <0.05.....	186
Figure 4.50	Effect of MenSCs treatment on apoptotic proteins expression in NAFLD mice. Western blot analysis revealed altered expression levels of Cytochrome C, BCL2, and BAX in the indicated groups (n=2). For all statistical plots, circles represent individual mice, and the data were presented as the mean \pm SEM. * <i>P</i> <0.05, ** <i>P</i> <0.01.	187

Figure 4.51	Representative heatmap showed key factors autophagy, ER stress, and oxidative stress regulation derived from RNA-seq data. Red indicated relatively higher expression levels, while blue signifies relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene (n=3).	189
Figure 4.52	GO enrichment analysis autophagy, ER stress, and oxidative stress related pathways. (A) Comparison between the HFD group and the NCD group. (B) Comparison between the HFD/MenSCs group and the HFD group.....	190
Figure 4.53	GSEA identified potential pathways related to autophagy, ER stress, and oxidative stress across different groups. The analysis includes comparisons between the NCD group and the HFD group, as well as between the HFD/MenSCs group and the HFD group....	191
Figure 4.54	Effect of MenSCs treatment on autophagy genes expression in NAFLD mice. qPCR analysis showed notably changes in the expression of <i>p62</i> , <i>LC3</i> , and <i>Beclin1</i> across the specified groups (n=4). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> <0.05, ** <i>P</i> <0.01, *** <i>P</i> <0.001.....	192
Figure 4.55	Effect of MenSCs treatment on autophagy proteins expression in NAFLD mice. Western blotting was used to assess the protein expression of p62 and LC3. In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> <0.05.	193
Figure 4.56	Effect of MenSCs treatment on ER stress genes expression in NAFLD mice. qPCR analysis showed significant changes in the expression of <i>ATF4</i> , <i>ATF6</i> , and <i>CHOP</i> across the specified groups (n=4). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> <0.05, *** <i>P</i> <0.001.....	194
Figure 4.57	Effect of MenSCs treatment on ER stress proteins expression in NAFLD mice. Western blotting was used to assess the protein expression of <i>ATF4</i> and p-eIF2 α . In all statistical plots, circles	

	represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> < 0.05, ** <i>P</i> < 0.01.	195
Figure 4.58	Effect of MenSCs treatment on ER stress genes expression in NAFLD mice. qPCR analysis showed significant changes in the expression of oxidative stress markers <i>NRF2</i> , <i>HO-1</i> , and <i>GCLC</i> across the specified groups (n=4). In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> <0.05, ** <i>P</i> <0.01.	196
Figure 4.59	Effect of MenSCs treatment on oxidative stress proteins expression in NAFLD mice. Western blotting was used to assess the protein expression of <i>NRF2</i> and <i>HO-1</i> . In all statistical plots, circles represent individual mice, with data presented as the mean \pm SEM. * <i>P</i> < 0.05.....	197
Figure 4.60	Histopathological assessment of NAFLD mouse livers. The extent of liver fibrosis was evaluated by Masson staining using liver tissues from the NCD group, the HFD group, and the HFD/MenSCs group. Scale bars:150 μ m.....	198
Figure 4.61	Representative heatmap showed key genes in fibrosis regulation derived from mRNA-seq data. Red indicated relatively higher expression levels, while blue signifies relatively lower expression levels. Each column corresponds to an individual sample, and each row to a specific gene (n=3).....	199
Figure 4.62	GO enrichment analysis of fibrosis related pathways. (A) Comparison between the HFD group and the NCD group. (B) Comparison between the HFD/MenSCs group and the HFD group.	200
Figure 4.63	GSEA identified potential pathways related to fibrosis across different groups. The analysis includes comparisons between the NCD group and the HFD group, as well as between the HFD/MenSCs group and the HFD group.	201
Figure 4.64	MenSCs regulated expression of fibrosis genes. qPCR analysis revealed significant changes in the expression of fibrosis markers	

	<i>Coll1a1</i> , <i>Col3a1</i> , <i>Ctgf</i> , <i>TGF-β</i> , and <i>α-SMA</i> across the specified groups (n=4). In all statistical plots, circles represent individual mice, with data presented as the mean ± SEM. * <i>P</i> <0.05, ** <i>P</i> <0.01, *** <i>P</i> <0.001.	202
Figure 5.1	MenSCs ameliorated ALD and NAFLD mice models by multiple functions.....	238
Figure 6.1	The therapeutic efficacy of MenSCs in managing ALD and NAFLD. MenSCs not only regulated lipid metabolism and enhanced insulin sensitivity but also reduced fat accumulation in the liver. Their anti-inflammatory properties were demonstrated by their ability to reduce pro-inflammatory cytokines and apoptosis. Additionally, MenSCs produced antioxidants and mitigated both oxidative stress and ER stress. In countering liver fibrosis, MenSCs played a prominent role by releasing anti-fibrotic factors and aiding in hepatocyte repair.	252

LIST OF SYMBOLS

α	Alpha
β	Beta
γ	Gamma
κ	Kappa
$\times g$	g-force
$^{\circ}C$	Degree Celsius
hr	Hour
μg	Microgram
mg	Milligram
kg	Kilogram
μl	Microliter
ml	Milliliter
μm	Micrometer
mM	Millimolar
μM	Micromolar
nM	Nanomolar
min	Minutes
rpm	Revolutions per minute
%	Percentage
TM	Trademark

LIST OF ABBREVIATIONS

AASLD	American association for the study of liver diseases
AC	Alcoholic cirrhosis
ADH	Alcohol dehydrogenase system
ADSCs	Adipose-derived stem cells
AFL	Alcoholic fatty liver
AH	alcoholic hepatitis
AKI	Acute kidney injury
ALC	Alcohol-associated cirrhosis
ALD	Alcohol-associated liver disease
ALDH	Aldehyde dehydrogenase
ALT	Alanine aminotransferase
AML12	alpha mouse liver 12 cells
AMPK	AMP-activated protein kinase
ASH	Alcohol steatohepatitis
ASK1	apoptosis signal-regulating kinase 1
AST	Aspartate aminotransferase
ATGL	Adipose TG lipase
AUD	Alcohol use disorder
Akt	protein kinase B
BAX	BCL2 associated x protein
BM	bone marrow
BM-MSCs	Bone marrow-derived mesenchymal stem cells
CAM	Cell adhesion molecule
CAMKK1	calcium/calmodulin-dependent protein kinase kinase 1

CKD	Chronic kidney disease
CM	conditioned medium
COT	Gene Cluster Acyl-CoA Thio esterase gene cluster
CPT-1A	Carnitine palmitoyl transferase 1A
CVD	Cardiovascular disease
Cyp4a10/Cyp4a14	Cytochrome P450 4a10/cytochrome P450 4a14
DAMPs	Damage-associated molecular patterns
DEGs	Differentially expressed genes
DIL	1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate
DMEM-HG	High glucose Dulbecco' s modified Eagle' s Medium
E2F1	E2F transcription factor 1
EASL	European association for the study of the liver
ECM	Extracellular matrix
EP	Eppendorf tube
ER	Endoplasmic reticulum
ERK	extracellular signal-regulated kinase
ESPEN	The European Society for Clinical Nutrition and Metabolism
ETC	Electron transport chain
EVs	extracellular vesicles
Exo	exosome
FASN	Fatty acid synthase
FBS	Fetal bovine serum
FDA	Food and drug administration
FFAs	Free fatty acids
FLD	Fatty liver disease
FTO	fat mass and obesity-related gene

GHT	Glucose Tolerance Test
GLP-1	Glucagon-like peptide-1
GMP	Good manufacturing practice
GO	Gene ontology
GSEA	Gene set enrichment analysis
GSH	glutathione
GTT	Glucose tolerance test
H&E	Hematoxylin & eosin
HCC	Hepatocellular carcinoma
HFD	High fat diet
HGF	Hepatocyte growth factor
HL	human liver
HNF4 α	hepatocyte nuclear factor 4 alpha
HO1	heme oxygenase 1
HP	High-protein diets
HSCs	Hepatic stellate cells
HepG2 cells	human liver carcinoma cells
HepaRG cells	human liver progenitor cells
IFN β	interferon β
IFN γ	interferon gamma
IHC	Immunohistochemical
IL-10	interleukin-10
IL-1 β	interleukin-1 beta
IL-6	interleukin 6
IL17	interleukin 17
IP	Intraperitoneal
IR	Insulin resistance

IRI	Ischemia-reperfusion injury
ITT	Insulin resistance test
IUA	Intrauterine adhesions
IV	Intravenous
JNK	c-Jun n-terminal kinase
KCs	Kupffer cells
Keap1	Kelch-like ECH-associated protein 1
L-02	human normal liver cell line
LD	Lipid droplet
LDL	low-density lipoprotein
LPA	Lysophosphatidic acid
LPAR1	lysophosphatidic acid receptor 1
LPCs	Lys phosphatidylcholines
LPS	Lipopolysaccharide
LT	Liver transplantation
MAFLD	Metabolic (dysfunction) associated fatty liver disease
MCD	methionine-choline deficient diet
MD	Mediterranean-style diets
MDA	malondialdehyde
MEOS	Microsomal ethanol oxidizing system
MMPs	Matrix metalloproteinases
MPK	AMP-activated protein kinase
MPO	Hepatic myeloperoxidase
MSC	Mesenchymal stem cells
MSCs	mesenchymal stem cell
MenSCs	Menstrual blood-derived mesenchymal stem cells
NAD ⁺	Nicotinamide adenine dinucleotide

NADH	Nicotinamide adenine dinucleotide
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
NCD	Normal chow diet
NCTC1469 cells	normal mouse hepatocytes
NF- κ B	nuclear factor kappa B
NIAAA	According to Alcohol Abuse and Alcoholism
NK	Natural killer
NLRs	NOD-like receptors
NQO-1	NAD(P)H quinone dehydrogenase 1
Nrf2	nuclear factor erythroid 2-related factor 2
OXPHOS	oxidative phosphorylation
PAMPs	Pathogen-associated molecular patterns
PAS	Periodic Acid Schiff
PI3K	phosphoinositide 3-kinase
POF	Premature ovarian failure
PPAR α	Peroxisome proliferator-activated receptor alpha
PV	per vaginal
RAS	renin-angiotensin system
ROS	reactive oxygen species
S1P	Sphingosine-1-phosphate
S1PR1	sphingosine-1-phosphate receptor 1
S1PR3	sphingosine-1-phosphate receptor 3
SERCA	the sarco-/endoplasmic reticulum (ER/SR) Ca ²⁺ ATPase
SGLT2	Sodium-glucose cotransporter-2
SHED	Stem cells from human exfoliated deciduous teeth
SHED-CM	human exfoliated deciduous teeth

SIP	sphingosine-1-phosphate
SIRT1	sirtuin 1
SREBP-1C	Sterol regulatory element-binding protein 1C
SkMSCs	skeletal muscle-derived mesenchymal stem cells
T2DM	Type 2 diabetes mellitus
TC	Total cholesterol
TG	Triglycerides
TGF- β	transforming growth factor β
TIMPs	Metalloproteinases
TLR4	toll-like receptor 4
TLRs	Toll-like receptors
TNF- α	tumor necrosis factor alpha
TUNEL	TdT-mediated dUTP nick end labeling
TWEAK	tumor necrosis factor-like weak inducer of apoptosis
UC-MSC	Umbilical cord mesenchymal stem cell
UPR	Unfolded protein response
WHO	World health organization
hSkMSCs	Human skeletal muscle satellite cell-derived mesenchymal stem cells
iNOS	inducible nitric oxide synthase
mTOR	mammalian target of rapamycin
rmTSG-6	recombinant mouse tumor necrosis factor-stimulated gene-6

LIST OF APPENDICES

- Appendix A Ethnical approval letters
- Appendix B The isolated of procedures of MenSCs
- Appendix C Transcriptome sequencing procedures and data analysis

**PENILAIAN MEKANISTIK SEL TUNJANG ENDOMETRIUM YANG
DIPEROLEH DARIPADA DARAH HAID DALAM MODEL MURIN
PENYAKIT HATI BERLEMAK ALKOHOLIK DAN BUKAN ALKOHOLIK**

ABSTRAK

Penyakit hati berlemak (FLD), yang merangkumi penyakit hati berlemak alkoholik (ALD) dan penyakit hati berlemak bukan alkoholik (NAFLD), merupakan penyakit hati kronik yang utama. ALD adalah antara 30 penyebab utama kematian di seluruh dunia, manakala prevalens NAFLD telah meningkat kepada 38%. Kedua-dua penyakit ini boleh berkembang kepada steatohepatitis, sirosis, dan akhirnya karsinoma hepatoselular (HCC), rawatan ubat yang tersedia pada masa ini mempunyai banyak kesan sampingan. Sel induk mesenkimal yang berasal daripada sel endometri atau darah haid manusia (MenSCs) menawarkan kelebihan yang ketara berbanding dengan sumber MSC yang lain kerana cara pengumpulan yang tidak invasif, akses etika yang lebih baik, hasilan yang lebih tinggi, dan kadar proliferasi yang tinggi. Oleh demikian, MenSCs berpotensi untuk digunakan sebagai pilihan terapeutik. Walau bagaimanapun, aplikasi khusus dan mekanisme MenSCs dalam merawat ALD dan NAFLD masih dalam tahap penyelidikan. Sehubungan dengan itu, kajian ini bertujuan untuk meneroka kesan terapeutik dan mekanisme molekul MenSCs terhadap ALD dan NAFLD dalam tikus. MenSCs pada awalnya diberikan kepada model tikus ALD yang diaruh dengan alkohol dan NAFLD yang diaruh dengan diet tinggi lemak untuk menilai kesan perlindungannya. Penilaian dilakukan berdasarkan pelbagai penanda biokimia, analisis histologi, penjujukan RNA, serta analisis gen dan protein untuk menjelaskan peranan MenSCs dalam merawat ALD dan NAFLD. Hasil kajian ini menunjukkan bahawa rawatan MenSCs telah memperbaiki fungsi hati secara

signifikan, melalui pengurangan ALT dan AST. Selain itu, pengurangan steatosis hepatic dan perubahan positif dalam ekspresi mRNA dan protein Fasn, Srebp1, SCD1, CPT1, Acadn, dan PPAR α menunjukkan bahawa metabolisme lipid juga bertambah baik selepas rawatan MenSCs. Perubahan signifikan pada IL-1 β , IL-10, TNF- α , IL-6, dan CCL2 selepas rawatan MenSCs membuktikan bahawa keradangan dan apoptosis juga berkurangan. MenSCs juga berjaya mengurangkan tekanan hepatic melalui pengawalturan proses autophagi, tekanan ER, dan penanda tekanan oksidatif seperti Beclin1, LC3, P62, ATF4, ATF6, CHOP, NRF2, HO-1, dan GCLC. Selain itu, pengurangan ekspresi Colla1, Ctgf, α -SMA, dan TGF- β serta pemulihan morfologi tisu menunjukkan bahawa fibrosis berkurang secara signifikan selepas rawatan MenSCs. Kesimpulannya, kajian ini berjaya membina model tikus ALD dan NAFLD dan menunjukkan bahawa MenSCs dapat mengawal fungsi hati, mengurangkan pengumpulan lemak, keradangan, dan apoptosis, mengurangkan tekanan ER dan tekanan oksidatif, mengurangkan fibrosis serta meningkatkan proses autofagi. Hasil daripada kajian ini menonjolkan potensi terapeutik MenSCs yang dapat digunakan untuk penyelidikan masa depan serta aplikasi klinikal dalam ALD dan NAFLD.

**MECHANISTIC EVALUATION OF MENSTRUAL BLOOD-DERIVED
ENDOMETRIAL STEM CELLS IN MURINE MODELS OF ALCOHOLIC
AND NON-ALCOHOLIC FATTY LIVER DISEASE**

ABSTRACT

Fatty liver disease (FLD), encompassing alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), is a major chronic liver condition. ALD is among the top 30 causes of death globally, while NAFLD prevalence has risen to 38%. Both conditions can progress to steatohepatitis, cirrhosis, or ultimately hepatocellular carcinoma (HCC), current available treatment drugs have many side effects. Human endometrial or menstrual blood-derived mesenchymal stem cells (MenSCs) offer significant advantages over other mesenchymal stem cells (MSC) sources due to their non-invasive collection, ethical accessibility, higher yield, and rapid proliferation rates, thus making them a promising therapeutic option. However, the specific applications and mechanisms of MenSCs in treating ALD and NAFLD are still under investigation. This study aimed to explore the therapeutic effects and molecular mechanisms of MenSCs on ALD and NAFLD in mice. MenSCs were initially administered to mouse models of ALD induced by alcohol and NAFLD induced by a high-fat diet to assess their protective effects. The evaluation utilized a comprehensive array of biochemical markers, histological analyses, RNA sequencing, and gene and protein analyses to elucidate the roles MenSCs in ameliorating ALD and NAFLD. The results showed that MenSCs treatment significantly improved liver function, as indicated by reductions in ALT and AST. Lipid metabolism improved, with decreased hepatic steatosis and favourable changes in mRNA and protein levels of *Fasn*, *Srebp1*, *SCD1*, *CPT1*, *Acadn*, and *PPAR α* . Inflammation and apoptosis were reduced, as evidenced by changes in

IL-1 β , IL-10, TNF- α , IL-6, and CCL2. MenSCs also alleviated hepatic stress by modulating autophagy, ER stress, and oxidative stress markers such as Beclin1, LC3, P62, ATF4, ATF6, CHOP, NRF2, HO-1, and GCLC. Additionally, fibrosis was significantly mitigated, as shown by decreased expression of Colla1, Ctgf, α -SMA, and TGF- β and improved tissue morphology. This study successfully established ALD and NAFLD mouse models and demonstrated that MenSCs administration effectively regulated liver function, reduced fat accumulation, inflammation, and apoptosis, mitigated ER stress and oxidative stress, alleviated fibrosis, and improved autophagy. These findings highlight the therapeutic potential of MenSCs and pave the way for future research and clinical applications in ALD and NAFLD.

CHAPTER 1

INTRODUCTION

1.1 Research Background

Fatty liver disease (FLD) is characterized by the accumulation of fat in more than 5% of liver cells, as observed through histology. FLD is classified into alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). ALD encompasses a spectrum of liver injuries caused by alcohol consumption, from simple fatty liver to more severe forms like alcoholic hepatitis, alcohol-related cirrhosis, and acute alcoholic steatohepatitis. This condition is commonly seen in individuals who consume more than one standard drink per day for women or more than two for men (Crabb *et al.*, 2020; Staufer and Stauber, 2023). On the other hand, NAFLD is diagnosed when there is evidence of liver fat accumulation ($\geq 5\%$) via imaging or histological analysis, in the context of minimal alcohol consumption (≤ 21 standard drinks per week for men and ≤ 14 standard drinks per week for women, where one standard drink equivalent to 14 grams of ethanol). The diagnosis of NAFLD also involves ruling out other potential causes of liver fat buildup, such as excessive alcohol use, prolonged use of fat-inducing medications, or genetic disorders. NAFLD is often linked to metabolic issues, such as obesity, diabetes, and dyslipidemia (Chalasani *et al.*, 2018; Staufer and Stauber, 2023).

1.1.1 Alcohol-associated liver diseases (ALD)

ALD and its severe complications caused by excessive alcohol consumption and can further progress into more serious issues including alcohol associated hepatitis (AH); which is severe form of alcohol steatohepatitis (ASH), alcohol-associated cirrhosis (AC), and hepatocellular carcinoma (HCC) (Wakil *et al.*, 2023). The

advancement of ALD is mainly associated with the amount and duration of alcohol usage. For example, initial stages of AH, occur when more than 50g of alcohol is consumed daily (Hoofnagle and Doo, 2024). Thus, this pathological condition is potentially reversible when alcohol consumption is reduced. However, its development is also shaped by genetic, epigenetic, and environmental influences (Higuera-de-la-Tijera *et al.*, 2022). The pathogenesis of ALD was summarized in Table 1.1.

Currently, 43% of the global population consume alcohol, and three million people die annually due to excessive alcohol consumption (Devarbhavi *et al.*, 2023). World Health Organization (WHO) reports that Europe consumes the highest amount of alcohol per capita annually and is followed by North and South America (Higuera-de-la-Tijera *et al.*, 2022). Likewise, alcohol use disorder (AUD) affects 5.1% of the worldwide population, with the European Region showing the greatest prevalence, followed by the Americas (Devarbhavi *et al.*, 2023). Around 35% of AUD individuals are likely to develop to ALD. Globally, excessive alcohol consumption is the main contributor to cirrhosis, accounting for nearly 60% of cirrhosis cases in Europe, North America, and Latin America. Excessive alcohol consumption is the main contributor to cirrhosis, accounting for nearly 60% of cirrhosis cases in North America, Europe, and Latin America (Stein *et al.*, 2016; Avila *et al.*, 2020).

1.1.2 Non-alcoholic fatty liver diseases (NAFLD)

NAFLD is a heterogeneous condition encompassing a wide range of liver disease. Recently, experts have recognized that the term NAFLD no longer aligns with the current understanding that metabolic dysfunction, rather than the mere absence of significant alcohol consumption or other known liver diseases, is the primary driver of fatty liver disease. Consequently, metabolic (dysfunction)-associated fatty liver

disease (MAFLD) has been recognized as a more accurate term, and a set of criteria has been established for diagnosing and assessing individuals with this condition (Gofton *et al.*, 2023). NAFLD or MAFLD has been identified as an emerging primary cause of fibrosis, steatosis, cirrhosis, and hepatocellular carcinoma (Sanyal *et al.*, 2021). The pathogenesis of NAFLD was summarized in Table 1.1.

Recent data suggests that the worldwide occurrence of NAFLD has grown by over 50% over the last three decades, with rates rising from 25.3% to 38.2% (Younossi *et al.*, 2023). Studies have also indicated that individuals with NAFLD face a higher risk of all-cause mortality compared to the general population, as well as an increased likelihood of developing extra-hepatic conditions, including cardiovascular disease (CVD), chronic kidney disease (CKD), and certain extra-hepatic cancers (Mantovani *et al.*, 2020b). Notably, immediate family members of those with NAFLD-related cirrhosis experience a remarkable 12-fold higher risk of developing advanced fibrosis due to genetic factors (Johnston *et al.*, 2020). In a similar light, upward trends in obesity, insulin resistance, type two diabetes, hypertension and cardiovascular disease have also been observed (Younossi *et al.*, 2019; Xie *et al.*, 2023). This comes as no surprise as the metabolic disorders mentioned above have been linked to NAFLD and this translates to increased healthcare burden globally (Golabi *et al.*, 2021).

Table 1.1 Comparison of the pathogenesis of ALD and NAFLD

Aspect	ALD	NAFLD	Ref.
Primary etiology	Excessive alcohol consumption	Metabolic dysfunction, obesity, insulin resistance	
Lipid accumulation	Alcohol promotes lipogenesis and inhibits fatty acid oxidation, leading to hepatic fat accumulation	Insulin resistance suppresses ATGL, increasing FFA influx into the liver while PPAR- α inactivation reduces fatty acid oxidation, further exacerbating steatosis	(Tanase <i>et al.</i> , 2020; Odriozola <i>et al.</i> , 2023)
Inflammation	Alcohol induces Kupffer cell activation, promoting the release of pro-inflammatory genes, which drive hepatocyte injury	Characterized by chronic inflammation, with increased levels of pro-inflammatory genes contributing to lipotoxic liver damage	(Chen <i>et al.</i> , 2020b; Dukic <i>et al.</i> , 2023)
Oxidative stress	Alcohol metabolism generates ROS, leading to lipid peroxidation and mitochondrial damage	Mitochondrial β -oxidation dysfunction generates ROS, increased oxidative stress	(Chen <i>et al.</i> , 2020b; Zhao <i>et al.</i> , 2021)
Continued			

ER stress	Ethanol metabolism disrupts ER homeostasis, leading to UPR activation	Hepatic lip toxicity and insulin resistance induces accumulation of misfolded proteins in the ER	(Chen <i>et al.</i> , 2020b; Xia <i>et al.</i> , 2020)
Fibrosis	Acetaldehyde and alcohol metabolites directly activate HSCs, leading to excessive ECM deposition and fibrosis progression	Chronic inflammation and metabolic stress activate TGF- β and HSCs, promoting fibrosis,	(Nassir, 2022; Subramaiyam, 2023)

Abbreviations: ATGL adipose triglyceride lipase, FFA increasing free fatty acid, UPR unfolded protein response, HSCs hepatic stellate cells, ECM extracellular matrix, ROS reactive oxygen species, TGF- β transforming growth factor- β .

1.2 Rationale and importance of the study

1.2.1 Rational and importance of MenSCs in ALD

Better treatment outcomes for ALD can be achieved if addressed before it progresses to the cirrhosis stage. The current treatment approaches for ALD emphasize key strategies, such as strict alcohol abstinence (Rogal et al., 2020; EASL, 2023), proper nutrition (Bischoff et al., 2020), and pharmacological interventions (Lieber et al., 2018). However, their efficacy remains limited, and patient adherence is often poor. While alcohol abstinence is the cornerstone of ALD management, the relapse rate is high, making long-term adherence challenging for many patients (Sehrawat et al., 2020; Mellinger et al., 2023). Pharmacological treatments, such as corticosteroids, are used in severe alcoholic hepatitis, yet their efficacy varies among individuals and is associated with increased risks of gastrointestinal bleeding and sepsis (Crabb et al., 2020). Other hepatoprotective agents, including N-acetylcysteine and S-adenosylmethionine, have been used as supportive therapies but lack robust clinical evidence (Liu et al., 2021). Once ALD progresses to liver fibrosis or cirrhosis, effective therapeutic options are scarce, and liver transplantation remains the only viable option for end-stage disease (Sehrawat et al., 2020). However, this approach is hindered by organ shortages, high costs, and the risk of post-transplant alcohol relapse (Terrault et al., 2023). Furthermore, chronic inflammation, oxidative stress, and gut microbiota dysbiosis, which play crucial roles in ALD pathogenesis, remain inadequately addressed by current treatments. This has prompted increasing research interest in novel therapeutic targets, such as inhibiting CYP2E1 and reducing reactive oxygen species (ROS), to develop more precise treatment approaches (Kong et al., 2019; Arab et al., 2020). Despite ongoing efforts, there are currently no officially approved

pharmacological therapies for ALD beyond risk factor management (Wong and Singal, 2019).

Mesenchymal stem cells (MSCs) are a diverse group of stem cells that originate from various tissues, including bone marrow, adipose tissue, and the umbilical cord, among others, have demonstrated significant potential in ameliorating a spectrum of liver metabolic disorders (Eom *et al.*, 2020; Watanabe *et al.*, 2021). The potential of MSCs as a treatment for liver diseases, including ALD, AH, and alcoholic cirrhosis, has been extensively studied in both experimental and clinical trials with no side effects (Suk *et al.*, 2016; Chung *et al.*, 2022). The effectiveness of MSC-based treatments in liver metabolic disorders is primarily attributed to their secretion of extracellular vesicles, various chemokines, and growth factors (Alfaifi *et al.*, 2018; Yang *et al.*, 2023). MSCs have been shown to mitigate ethanol-induced liver injury and steatosis, reduce hepatic lipid accumulation, and enhance liver function (Wan *et al.*, 2020a). Additionally, MSCs exert anti-inflammatory effects (Chung *et al.*, 2022) and alleviate oxidative stress in ALD (Wan *et al.*, 2020a; Wan *et al.*, 2020b). Notably, pre-conditioning human adipose-derived mesenchymal stem cells (hADMSCs) with lysophosphatidic acid (LPA) and/or sphingosine-1-phosphate (S1P) significantly attenuated lipid accumulation, inflammation, oxidative stress, and fibrosis, while simultaneously enhancing the activity of alcohol-metabolizing enzymes and improving liver function (Li *et al.*, 2018).

MenSCs, a notable subset of MSCs, are noteworthy for their non-invasive collection method, ethical accessibility, higher concentration, and rapid proliferation rates (Liu *et al.*, 2018). These cells exhibit characteristics similar to other MSCs, such as spindle-shaped morphology, the capability to differentiate into the classical trilineage, and the presence of specific surface markers (Liu *et al.*, 2018; Chen *et al.*,

2019a; Chen *et al.*, 2019b; Chen *et al.*, 2020a). Despite comprehensive investigations into the applications of MenSCs in diverse metabolic disease models (Chen *et al.*, 2017; Du *et al.*, 2023), the understanding of their effects and potential mechanisms in the treatment of ALD remains limited.

1.2.2 Rational and importance of MenSCs in NAFLD

The management of NAFLD primarily focuses on weight management, dietary modifications, and physical activity. However, patient adherence remains a major challenge, leading to persistent disease progression (Rong *et al.*, 2022). Currently, there are no FDA approved pharmacological therapies specifically for NAFLD (Wong and Singal, 2019). Among the available options, vitamin E and pioglitazone have demonstrated some therapeutic benefits, yet their clinical applications are restricted by significant adverse effects. While vitamin E has been shown to reduce hepatic steatosis and inflammation, prolonged use may increase the risks of bleeding, prostate cancer, and heart failure (Rinella *et al.*, 2023). Similarly, pioglitazone improves insulin resistance but is associated with weight gain, bladder cancer, and cardiovascular complications (Cusi *et al.*, 2022). Recently, GLP-1 receptor agonists have shown promise in NAFLD management, but their long-term safety and tolerability require further investigation (Mantovani *et al.*, 2020a; Mantovani and Dalbeni, 2021). Furthermore, once NAFLD progresses to liver fibrosis or cirrhosis, effective reversal therapies remain unavailable, and current management primarily focuses on symptom control and complication management (Nassir, 2022). Given the strong association between NAFLD and metabolic syndrome, research is increasingly directed toward targeting inflammation, oxidative stress, and metabolic dysregulation, though these approaches are still in preclinical or early clinical trial stages (Rong *et al.*, 2022).

Emerging evidence has demonstrated the therapeutic potential of MSCs in the treatment of NAFLD with no side effects. MSCs and their extracellular vesicles (MSCs-Exos) have drawn particular attention for their capability to regulate lipid metabolism (Li et al., 2019a; Cheng et al., 2021), modulate inflammation and apoptosis (Xu et al., 2020; Yang et al., 2021), and alleviate reactive oxygen species (ROS) accumulation, endoplasmic reticulum (ER) stress, and oxidative stress in NAFLD (Bi et al., 2021; Du et al., 2022a). MSC treatment has also been shown to contribute to an almost 50% reduction in collagen levels in NASH (Wang et al., 2018a; Nickel et al., 2022).

Given the advantages of MenSCs presented in the earlier sub-chapter 1.2.1, it could be a good option for NAFLD. However, their effects and underlying mechanisms in the treatment of NAFLD remain inadequately understood and require further investigation.

1.3 Hypothesis and objective of the study

1.3.1 Hypothesis

Null Hypothesis

MenSCs does not ameliorate ALD and NAFLD in mouse models.

Alternative Hypothesis (Hypothesis of this study)

MenSCs regulates lipid and glucose metabolism, inflammation, oxidative stress, ER stress, autophagy, and fibrosis in ALD/NAFLD.

1.3.2 Objective of the study

The primary aim of this study is to elucidate the therapeutic effects and molecular mechanisms of MenSCs in alleviating ALD and NAFLD. The specific objectives of this study are as outlined below:

1. To establish mouse models for ALD and NAFLD studies.
2. To study the influence of MenSCs on hepatic metabolism in the ALD and NAFLD.
3. To understand the modulatory functions of MenSCs in ALD and NAFLD associated lipid and glucose metabolism.
4. To investigate the roles of MenSCs in alleviation of ALD and NAFLD through anti-inflammatory and anti-apoptotic processes.
5. To evaluate the efficacy of MenSCs on reducing oxidative stress, ER stress, and autophagy in ALD and NAFLD.

6. To assess the effectiveness of MenSCs in reducing ALD and NAFLD associated liver fibrosis.

CHAPTER 2

LITERATURE REVIEW

2.1 Overview of alcohol-associated liver disease (ALD)

2.1.1 The prevalence of ALD

Alcohol misuse is a global health crisis, which stands as the primary etiological factor for liver disease (Hernandez-Evole et al., 2023). It increases the risk of death from liver disease by 260 times, while cardiovascular and cancer mortalities rates increase by factors of 3.2 and 5.1, respectively (Hagstrom et al., 2021; Devarbhavi et al., 2023). The overall prevalence of ALD in Asia was 4.81%, showing a significant upward trend over time. It increased from 3.82% between 2000 and 2010 to 6.62% between 2011 and 2020 (Xu et al., 2022). Additionally, alcohol is the top cause of cirrhosis worldwide, accounting for nearly half of all cirrhosis case globally. Moreover, the occurrence of alcohol-associated hepatitis has risen over the past few years (Arab *et al.*, 2019; Devarbhavi *et al.*, 2023). In Malaysia, alcohol-attributable liver disease remains a significant concern, with alcohol-related cirrhosis accounting for 9.48% of cases and alcohol-attributable hepatocellular carcinoma (HCC) comprising 5.80% of cases (Xu et al., 2022).

ALD, which is associated with excessive alcohol consumption, ranks among the top 30 causes of death globally and represents one of the most significant chronic liver conditions (Thursz *et al.*, 2019). AFLD, the initial stage of ALD, is presumably on the rise parallel to metabolic syndrome (Hamaguchi *et al.*, 2020). Recent data indicated an increase in the prevalence of ALD among male drinkers, rising from 22.3% in earlier cohorts to 36.6% in recent cohorts (Hamaguchi *et al.*, 2020). Results differed throughout the range of ALD, with the non-liver mortality rate at 43.4 per 1000 patient-

years in alcohol-related fatty liver and 22.5 per 1000 patient-years in alcoholic hepatitis. ALD patients faced a greater risk for all examined outcomes, with the relative risks of mortality linked to cardiovascular diseases (CVD), non-hepatic cancer, and infections (Theodoreson *et al.*, 2023). Furthermore, increased metabolic disturbances such as hyperglycaemia have shown both in men and women with ALD as compared to the normal population (25.4% vs 43.0% and 25.1% vs 39.1%) (Hamaguchi *et al.*, 2020).

2.1.2 ALD pathogenesis

The pathogenesis of ALD is multifactorial, involving intricate interactions among genetic, epigenetic, and environmental factors. Factors like alcohol, drinking habits, age and gender, obesity, ethnicity, smoking, and genetic predispositions are intricately associated with the onset and progression of ALD (Suresh *et al.*, 2020; Higuera-de-la-Tijera *et al.*, 2022). In the progression of ALD, various comorbidities may occur, including alcohol use disorders, cardiovascular and digestive issues, chronic infections, diabetes, and immunodeficiency (such as HIV/AIDS) (Mackowiak *et al.*, 2024). ALD includes a range of hepatic disorders, from simple steatosis, also known as alcoholic fatty liver (AFL), to more serious conditions like steatohepatitis, cirrhosis or fibrosis, and ultimately hepatocellular carcinoma (HCC) (Figure 2.2) (Zhao *et al.*, 2021).




Figure 2.1 Spectrum of ALD, risk factors, and comorbidities (Mackowiak et al., 2024).

2.1.2(a) Dysregulation of alcohol metabolic pathways

About 90% of alcohol is eliminated by the liver (Jones, 2019). Alcohol is metabolized within the liver through three distinct enzymic pathways namely the cytosolic alcohol dehydrogenase system (ADH), the microsomal ethanol oxidizing system (MEOS) present in the endoplasmic reticulum, and the catalase oxidation pathway situated in peroxisomes (Figure 2.3). Predominantly, the ADH and MEOS pathways are responsible for the breakdown of alcohol, accounting for 80-90% and 10-20% of its metabolism, respectively, with less than 2% occurring through the catalase pathway (Wu *et al.*, 2023).

Alcohol metabolism is primarily facilitated by the action of cytosolic ADH, which catalyses the oxidative conversion of alcohol into acetaldehyde. The process involves the transfer from the alcohol molecule to nicotinamide adenine dinucleotide (NAD⁺), resulting in its reduction to NADH and the concomitant production of acetaldehyde (Buchanan and Sinclair, 2021). The excessive metabolism of alcohol

generates free radicals that compromises the stability of ADH, reducing its activity and thereby inhibiting the ADH metabolic pathway. A high NADH/NAD⁺ ratio affects carbohydrate metabolism and suppresses β -oxidation of fatty acids culminating in lipid accumulation in hepatic, thus precipitating early onset of fatty liver disease (Ceni *et al.*, 2014). Furthermore, this imbalance may cause an excessive flow of electrons in the mitochondrial electron transport system, with electrons accumulating and leaking at complexes I and III. This results in the generation of reactive oxygen species (ROS), triggering oxidative stress in liver (Edenberg, 2007; Kourkoumpetis and Sood, 2019; Zhao *et al.*, 2021).

MEOS is a metabolic pathway based on the cytochrome P450 enzyme system, which is predominantly located on the endoplasmic reticulum of liver cells. The various cytochrome P450 isozymes, CYP2E1 is the most crucial for catalysing the oxidation of alcohol (Buchanan and Sinclair, 2021). MEOS is an oxygen-consuming pathway that not only metabolizes alcohol but also generates a significant amount of ROS, resulting in oxidative stress in the liver (Liu *et al.*, 2021). Some free radicals can directly bind with ethanol to form hydroxyethyl free radicals. These hydroxyethyl free radicals reduce the activity of certain metabolic enzyme systems and the efficacy of functional glycoproteins in the liver. They also specifically bind with glutathione (GSH) to form stable complexes, leading to a decrease in GSH levels in the liver, which inhibits its resynthesis and thereby reduces the liver's ability to manage oxidative stress (Iain H McKillop, 2016; Teschke, 2018). The excessive accumulation of free radicals can also trigger lipid peroxidation within liver cells, thus compromising their membrane integrity, and leading to pathological changes which result in apoptosis (Teschke, 2018, 2019).




Figure 2.2 Metabolic pathways affected in the liver by excessive consumption (Xiao, 2020).

2.1.2(b) Dysregulation of metabolic pathways in the liver by excessive consumption of alcohol

Excessive alcohol consumption has been associated with the development of ALD due to the lipid accumulation such as triglycerides, cholesterol esters, and phospholipids within hepatocytes (Zhao *et al.*, 2021). This accumulation can progress through various stages of steatosis to AH, characterized by cellular ballooning and lobular inflammation (Zhao *et al.*, 2021). The activation of hepatic stellate cells plays a vital role in the development of alcohol-induced hepatic fibrosis, which potentially leads to cirrhosis (Buchanan and Sinclair, 2021). Chronic alcohol intake is also a recognized cause of HCC, with implicated mechanisms including acetaldehyde toxicity, cytochrome P450E1 enzyme, angiogenesis induction, angiogenesis, and

oncogene mutations (Huang *et al.*, 2023). Despite extensive research, the full mechanisms behind ALD are not yet completely understood. Nevertheless, a summary of the current knowledge is presented in the subsequent sub-sections.

2.1.2(b)(i) Lipid accumulation

Alcohol has been recognized as a significant inducer of hepatic lipid accumulation through various mechanisms affecting those fat mechanisms (Ceni *et al.*, 2014). Specifically, alcohol intake raises the levels reduced NADH in hepatocytes, which in turn inhibits mitochondrial β -oxidation of fatty acids, culminating in steatosis (Herzig and Shaw, 2018). Additionally, the upregulation of SREBP1 and PPAR α further promote the accumulation of hepatic fat (Yue *et al.*, 2021; Odriozola *et al.*, 2023).

Additional mechanisms also contribute significantly, notably the transformation of acetate, produced during acetaldehyde metabolism, into acetyl-CoA, a crucial precursor for synthesizing fatty acids (Odriozola *et al.*, 2023). The consumption of alcohol also triggers lipolysis and adipocyte apoptosis, thereby increasing the concentrations of circulating fatty acids and accumulation in the liver (Odriozola *et al.*, 2023). Furthermore, an enhanced lipid supply from the small intestine to the liver has been identified as a factor that facilitates the onset of steatosis (Herzig and Shaw, 2018).

2.1.2(b)(ii) Increase in inflammatory response

Alcohol and its metabolites, such as ROS, acetaldehyde, acetate, and lipopolysaccharide (LPS) derived from intestinal microbes, are pivotal in the development of ALD. These compounds significantly contribute to the inflammatory processes associated with ALD (Zhao *et al.*, 2021; Dukic *et al.*, 2023). Notably,

acetaldehyde and ROS are particularly detrimental to liver health, significantly contributing to inflammation (Le Dare *et al.*, 2019).

The inflammatory response in ALD involves not only immune system cells but also various resident liver cells like Kupffer cells and hepatic stellate cells. They are activated by a diverse array of exogenous and endogenous antigens (Dukic *et al.*, 2023). Specifically, hepatic inflammation is primarily triggered by gut-derived pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) released from stressed or dying hepatocytes (Seitz *et al.*, 2018). These PAMPs and DAMPs are recognized by Toll-like receptors (TLRs) and NOD-like receptors (NLRs) expressed on both immune cells and parenchymal cells in the liver. This recognition triggers the secretion of chemokines and cytokines, which further amplify the inflammatory response (Dukic *et al.*, 2023). For example, LPS, a PAMP derived from gut bacteria, is recognized by TLR4. This binding activates NF- κ B, resulting in the generation of pro-inflammatory chemokines and cytokines (Guijarro-Munoz *et al.*, 2014). Additionally, LPS stimulates Kupffer cells through the TLR4-mediated pathway, resulting in the release of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1, along with key pro-inflammatory cytokines like IL-1, IL-6, and TNF- α , further intensifying the inflammatory response in ALD (Slevin *et al.*, 2020).

2.1.2(b)(iii) Accumulation of ROS and increase in oxidative stress

Exposure to alcohol results in liver injury through the modulation of various cellular processes, notably involving the generation of ROS and the resulting oxidative stress (Zhao *et al.*, 2021; Sundar and Saraswathi, 2023).

The generation of ROS related to alcohol consumption involves multiple pathways, primarily the induction of the enzyme CYP2E1 and alcohol-induced

inflammation (Leung and Nieto, 2013; Harjumaki *et al.*, 2021). The enzyme CYP2E1 plays a vital role in enhancing the activity of NADPH oxidase. This increased activity accelerates the mitochondrial transport of reduced NADH, leading to increased electron leakage from the mitochondrial respiratory chain of hepatocyte and, consequently, elevated ROS production (Harjumaki *et al.*, 2021). In the context of alcohol-induced inflammation, the generation of tumour necrosis factor (TNF) is implicated in facilitating the interaction between N-acetyl sphingosine and mitochondria, ultimately contributing to further ROS generation (Zhao *et al.*, 2021; Dukic *et al.*, 2023). Additionally, acetaldehyde, produced via both non-oxidative and oxidative metabolic pathways of alcohol, is a toxic compound that causes mitochondrial alterations. These alterations include a decrease in ATP generation through the respiratory chain and additional ROS generation in hepatocytes (Odriozola *et al.*, 2023). Moreover, alcohol itself is toxic and promotes oxidative stress, further mediated by ROS (Liu *et al.*, 2021).

Oxidative stress in the liver fundamentally stems from a disproportion between ROS and antioxidants. This condition is often triggered by the overproduction of ROS, leading to oxidative stress in liver, a key contributor in alcohol-induced liver damage (Kourkoumpetis and Sood, 2019; Zhao *et al.*, 2021).

2.1.2(b)(iv) Increase in endoplasmic reticulum (ER) stress

Alcohol consumption leads to the buildup of misfolded or unfolded proteins within the ER lumen, then triggering ER stress. The stress activates unfolded protein response (UPR) to maintain ER homeostasis. The UPR mitigates ER stress by decreasing protein synthesis, enhancing the production of enzymes involved in protein folding, and promoting protein degradation (Maiers and Malhi, 2019; Buyco *et al.*, 2021). Nonetheless, prolonged alcohol intake could exacerbate ER stress. Prolonged

ER stress may surpass the adaptive capabilities of the UPR, resulting in additional disruptions in hepatocyte function (Xia *et al.*, 2020).

Alcohol metabolism and the resulting ROS are key factors to ER stress. During alcohol metabolism via the ADH and MEOS pathways, substantial amounts of NADH or NADP⁺ are produced, leading to ROS accumulation. An overproduction of ROS can disrupt the redox equilibrium in the ER, impairing the function of disulfide bond isomerases and leading to the buildup of unfolded proteins, which triggers ER stress (Aghara *et al.*, 2023). Additionally, alcohol disrupts lipid metabolism, further contributing to ER stress. Dysregulation of lipid metabolism caused by alcohol can result in lipid accumulation in the ER membrane, resulting in activation of the UPR and ER stress (Xia *et al.*, 2020). Moreover, free fatty acids can disrupt protein folding and contribute to ER stress (Lepretti *et al.*, 2018). Changes in the composition and amount of lipids in the ER membrane can alter its fluidity and impair the function of membrane proteins, further leading to ER stress (Na *et al.*, 2023). In ALD, chronic ER stress and UPR activation can result in lipid metabolic disorders, hepatocyte inflammation, and apoptosis, contribute to the progression of liver inflammation and fibrosis (Liu and Green, 2019; Na *et al.*, 2023).

2.1.2(b)(v) Inhibition of autophagy

Autophagy is a dynamic process that is crucial for targeting damaged and excess cytoplasmic organelles for lysosomal degradation. This mechanism significantly counteracts the harmful effects of ROS causes oxidative stress, a key driver in the advancement of ALD (Salete-Granado *et al.*, 2023). Autophagy is essential not only for regulating hepatocyte function but also for affecting non-parenchymal cells, including macrophages, endothelial cells, and hepatic stellate cells, all of which are pivotal in the development of liver disease (Allaire *et al.*, 2019).

In the context of ALD, acute alcohol exposure initially induces a protective and adaptive autophagy. However, chronic alcohol exposure suppresses hepatic autophagy, thereby contributing to the progression of ALD (Qian et al., 2021a). This suppression, termed “insufficient autophagy”, involved decreased lysosome number and impaired lysosomal functions in hepatocytes (Chao et al., 2018a). Experimental models in mice with chronic alcohol feeding plus acute binge (Gao-binge) demonstrate autophagy insufficiency and liver injury (Chao et al., 2018b). Concurrently, ER stress, occurring alongside oxidative stress and mitochondrial dysfunction, further complicates the autophagy landscape in ALD (Liu and Green, 2019). This complex relationship intertwines with apoptosis induced by ER stress, involving critical signalling pathways like PERK/ATF4, IRE1 α , ATF6, and Ca²⁺ (Song et al., 2017). Moreover, apoptosis-related proteins can hinder autophagy by breaking down vital autophagy-associated proteins (Song et al., 2017).

2.1.2(b)(vi) Acceleration of fibrosis and cirrhosis

Liver fibrosis and cirrhosis in ALD primarily arise from alcohol-induced hepatocyte injury, inflammation, and subsequent immune responses that activate hepatic stellate cells (HSCs) (Nagy et al., 2016). These cells migrate, proliferate, and enhance extracellular matrix (ECM) deposition, driving the fibro genic process (Nagy et al., 2016).

The activation of HSCs plays a crucial role in the development of liver fibrosis and cirrhosis in ALD. Alcohol or acetaldehyde-induced hepatocellular damage leads to the release of hedgehog ligands (Subramaiyam, 2023). These ligands activate hedgehog-responsive genes and HSCs through a paracrine mechanism, resulting in ECM deposition in sinusoidal areas and around swollen hepatocytes, leading to pseudo lobular formation (Lackner and Tiniakos, 2019). Other crucial pathways in HSC

activation involve Kupffer cell activation and the release of growth factors and chemokines. These processes are stimulated by DAMPs from dead hepatocytes, and by PAMPs and LPS translocating from a compromised gut due to alcohol (Fujii and Kawada, 2014; Nagy *et al.*, 2016). Moreover, the fibrogenesis process is sustained by ECM components like collagen-1 and integrin, which support the survival of activated HSCs. Conversely, alcohol consumption hinders the natural killer (NK) cell-mediated clearance of HSCs (Seitz *et al.*, 2018; Lackner and Tiniakos, 2019; Zhao *et al.*, 2022b). Activated HSCs produce tissue inhibitors of metalloproteinases (TIMPs), which inhibit the fibrolytic activity of matrix metalloproteinases (MMPs). Combined with hepatocyte loss in septal PCF regions, this contributes to the progression of fibrosis, marked by denser collagen deposition and the buildup of elastic fibres and clusters. The continuous fibrogenesis and loss of liver parenchyma ultimately disrupt the lobular architecture, leading to cirrhosis (Lackner and Tiniakos, 2019; Zhao *et al.*, 2022b).

2.1.2(b)(vii) Induction of apoptosis

Alcohol metabolism in hepatocytes triggers apoptosis through both the extrinsic (death receptor) and intrinsic (mitochondria) pathways (Subramaiyam, 2023). The extrinsic pathway involves the activation of death receptors, which is induced by alcohol-induced ER stress, ROS production, and increased gut permeability. This leads to the liver influx of LPS derived from the gut microbiome, activating hepatocytes and Kupffer cells. Consequently, pro-inflammatory cytokines are triggered. These cytokines initiate death receptor signalling, leading to apoptosis and necroptosis mediated by caspase-8 activity (Miyata and Nagy, 2020). Meanwhile, oxidative stress triggers the intrinsic pathway, leading to DNA damage and alterations in growth factors (Shojaie *et al.*, 2020). This results in mitochondrial dysfunction, causing

cytochrome c to be released into the cytoplasm. There, it combines with Apaf-1 and caspase 9 to forming the apoptosome, which subsequently triggers the activation of downstream caspases 3, 6 and 7 to carry out apoptosis (Namachivayam and Valsala Gopalakrishnan, 2021; Subramaiyam, 2023).

2.1.3 Current management and treatment strategies for ALD

The medical management of ALD emphasizes several key strategies which includes unwavering alcohol abstinence, ensuring adequate nutritional support, early detection and treatment of infections, addressing conditions such as acute kidney injury (AKI), managing the complications resulting from portal hypertension, and, in specific cases, employing corticosteroids. Furthermore, recent guidelines provide a detailed treatment framework for ALD which includes target therapies as well (Arab et al., 2023).

2.1.3(a) Alcohol abstinence: a core management strategy

Complete alcohol abstinence is crucial in improving clinical outcomes across all disease stages and for reducing mortality rates in ALD (Rogal *et al.*, 2020). For ALD patients, particularly those with AH or cirrhosis, even minimal alcohol consumption poses substantial risks. These risks include an increased likelihood of decompensating events, including variceal bleeding, ascites, and hepatic encephalopathy, a higher incidence of HCC, elevated recurrence rates of cirrhosis and mortality after transplantation, and an overall rise in liver-related mortality (Mellinger et al., 2023). In cases of severe ALD, assessment by a cessation team, which include psychiatrists and addiction specialists, is essential in addition to the recommendation of medications such as baclofen, lorazepam, and oxazepam (Cabezas, 2022).

Studies indicate that approximately 30% of patients maintain complete abstinence during follow-up (Lackner et al., 2017). However, achieving total abstinence is challenge for patients with alcohol induced liver disease as relapse rates remain high (Sehrawat *et al.*, 2020; Mellinger *et al.*, 2023). Regarding abstinence, although 27% of patients with ALD may achieve histological normalization by abstinence from alcohol, 18% still at risk progressing to cirrhosis (Lackner et al., 2017). While abstinence does not assure full recovery from the disease, it is crucial to ALD management. These findings highlight the importance of early diagnosis and intervention in ALD, emphasizing the need for both abstinence and complementary treatment strategies.

2.1.3(b) Nutritional support in ALD care

In the context of advanced ALD, malnutrition, sarcopenia, and frailty pose significant risks. These conditions often resulting from protein damage and can increase the susceptibility to bacterial infections in individuals with ALD (Kong *et al.*, 2019; Ayares *et al.*, 2022). Malnutrition, particularly in those with AH, closely correlates with disease severity, complications, and mortality (Simonetto *et al.*, 2020).

The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends that individuals with AH consume 1.2-1.5 g/kg of protein and 30-35 kcal/kg daily, increasing to 1.5 g/kg protein and 40 kcal/kg for patients with decompensated cirrhosis (Bischoff *et al.*, 2020). Nutritional supplements, including vitamin B, zinc, and vitamin D, are essential for maintaining calorie intake, reducing infection, and improving liver function (Bischoff *et al.*, 2020). Nutritional supplementation, as demonstrated in multiple randomized studies, supports the maintenance of necessary caloric intake and has been demonstrated to reduce the occurrence of infections, hasten the resolution of hepatic encephalopathy, and improve